Shelley A Henderson1, Nazleen Muhammad Gowdh2, Colin A Purdie3, Lee B Jordan3, Andrew Evans4, Tracy Brunton5, Alastair M Thompson6, Sarah Vinnicombe4. 1. 1 Department of Medical Physics, Ninewells Hospital , Dundee , UK. 2. 2 Department of Radiology, Aberdeen Royal Infirmary , Aberdeen , UK. 3. 3 Department of Pathology, Ninewells Hospital , Dundee , UK. 4. 4 Division of Imaging and Technology, University of Dundee , Dundee , UK. 5. 5 MRI Department, Clinical Research Centre, University of Dundee , Dundee , UK. 6. 6 Department of Breast Surgical Oncology, University of Texas MD Anderson Cancer Center , Houston, TX , USA.
Abstract
OBJECTIVE: Does method of tumour volume measurement on MRI influence prediction of treatment outcome in patients with primary breast cancer undergoing neoadjuvant chemotherapy (NAC)?. METHOD: The study comprised of 136 women with biopsy-proven breast cancer scheduled for MRI monitoring during NAC treatment. Dynamic contrast-enhanced images were acquired at baseline (pre-NAC) and interim (post three NAC cycles) time points. Functional tumour volumes (FTVs), automatically derived using vendor software and enhancing tumour volumes (ETVs), user-derived using a semi-automated thresholding technique, were calculated at each time point and percentage changes calculated. Response, assessed using residual cancer burden (RCB) score on surgically resected specimens, was compared statistically with volumetric changes and receiver operating characteristic analysis performed. RESULTS: Mean volumetric differences for each RCB response category were (FTV/ETV): pathological complete response (pCR) 95.5/96.8%, RCB-I 69.8/66.7%, RCB-II 64.0/65.5%, RCB-III 25.4/24.0%. Differences were significant between pCR and RCB-II/RCB-III categories (p < 0.040; unpaired t-test) using FTV measures and between pCR and RCB-I/RCB-II/RCB-III categories (p < 0.006; unpaired t-test) when ETV was used. Receiver operating characteristic analysis for pCR identification post-NAC yielded area under the curve for FTV/ETV of 0.834/0.920 respectively. Sensitivity and specificity for FTV was 80.0 and 76.8% for FTV and 81.0 and 91.8% for ETV. CONCLUSION: ETV changes can identify patients likely to achieve a complete response to NAC. Potentially, this could impact patient management regarding the possible avoidance of post-NAC surgery. Advances in Knowledge: Interim changes in ETV are more useful than FTV in predicting final pathological response to NAC. ETV differentiates patients who will achieve a complete response from those who will have residual disease.
OBJECTIVE: Does method of tumour volume measurement on MRI influence prediction of treatment outcome in patients with primary breast cancer undergoing neoadjuvant chemotherapy (NAC)?. METHOD: The study comprised of 136 women with biopsy-proven breast cancer scheduled for MRI monitoring during NAC treatment. Dynamic contrast-enhanced images were acquired at baseline (pre-NAC) and interim (post three NAC cycles) time points. Functional tumour volumes (FTVs), automatically derived using vendor software and enhancing tumour volumes (ETVs), user-derived using a semi-automated thresholding technique, were calculated at each time point and percentage changes calculated. Response, assessed using residual cancer burden (RCB) score on surgically resected specimens, was compared statistically with volumetric changes and receiver operating characteristic analysis performed. RESULTS: Mean volumetric differences for each RCB response category were (FTV/ETV): pathological complete response (pCR) 95.5/96.8%, RCB-I 69.8/66.7%, RCB-II 64.0/65.5%, RCB-III 25.4/24.0%. Differences were significant between pCR and RCB-II/RCB-III categories (p < 0.040; unpaired t-test) using FTV measures and between pCR and RCB-I/RCB-II/RCB-III categories (p < 0.006; unpaired t-test) when ETV was used. Receiver operating characteristic analysis for pCR identification post-NAC yielded area under the curve for FTV/ETV of 0.834/0.920 respectively. Sensitivity and specificity for FTV was 80.0 and 76.8% for FTV and 81.0 and 91.8% for ETV. CONCLUSION: ETV changes can identify patients likely to achieve a complete response to NAC. Potentially, this could impact patient management regarding the possible avoidance of post-NAC surgery. Advances in Knowledge: Interim changes in ETV are more useful than FTV in predicting final pathological response to NAC. ETV differentiates patients who will achieve a complete response from those who will have residual disease.
Authors: Savannah C Partridge; Jessica E Gibbs; Ying Lu; Laura J Esserman; Debasish Tripathy; Dulcy S Wolverton; Hope S Rugo; E Shelley Hwang; Cheryl A Ewing; Nola M Hylton Journal: AJR Am J Roentgenol Date: 2005-06 Impact factor: 3.959
Authors: Mariann G Heldahl; Steinar Lundgren; Line R Jensen; Ingrid S Gribbestad; Tone F Bathen Journal: J Magn Reson Imaging Date: 2011-07-14 Impact factor: 4.813
Authors: Nola M Hylton; Jeffrey D Blume; Wanda K Bernreuter; Etta D Pisano; Mark A Rosen; Elizabeth A Morris; Paul T Weatherall; Constance D Lehman; Gillian M Newstead; Sandra Polin; Helga S Marques; Laura J Esserman; Mitchell D Schnall Journal: Radiology Date: 2012-06 Impact factor: 11.105
Authors: Nola M Hylton; Constantine A Gatsonis; Mark A Rosen; Constance D Lehman; David C Newitt; Savannah C Partridge; Wanda K Bernreuter; Etta D Pisano; Elizabeth A Morris; Paul T Weatherall; Sandra M Polin; Gillian M Newstead; Helga S Marques; Laura J Esserman; Mitchell D Schnall Journal: Radiology Date: 2015-12-01 Impact factor: 11.105
Authors: G Bonadonna; P Valagussa; C Brambilla; L Ferrari; A Moliterni; M Terenziani; M Zambetti Journal: J Clin Oncol Date: 1998-01 Impact factor: 44.544
Authors: W Fraser Symmans; Florentia Peintinger; Christos Hatzis; Radhika Rajan; Henry Kuerer; Vicente Valero; Lina Assad; Anna Poniecka; Bryan Hennessy; Marjorie Green; Aman U Buzdar; S Eva Singletary; Gabriel N Hortobagyi; Lajos Pusztai Journal: J Clin Oncol Date: 2007-09-04 Impact factor: 44.544
Authors: Nazia F Jafri; David C Newitt; John Kornak; Laura J Esserman; Bonnie N Joe; Nola M Hylton Journal: J Magn Reson Imaging Date: 2013-12-18 Impact factor: 4.813
Authors: Bruna M Thompson; Luciano F Chala; Carlos Shimizu; Max S Mano; José R Filassi; Felipe C Geyer; Ulysses S Torres; Giselle Guedes Netto de Mello; Cláudia da Costa Leite Journal: Eur Radiol Date: 2021-10-30 Impact factor: 7.034
Authors: Jeanine E Vasmel; Maureen L Groot Koerkamp; Stefano Mandija; Wouter B Veldhuis; Maaike R Moman; Martijn Froeling; Bas H M van der Velden; Ramona K Charaghvandi; Celien P H Vreuls; Paul J van Diest; A M Gijs van Leeuwen; Joost van Gorp; Marielle E P Philippens; Bram van Asselen; Jan J W Lagendijk; Helena M Verkooijen; H J G Desirée van den Bongard; Antonetta C Houweling Journal: Adv Radiat Oncol Date: 2021-11-20